Creo Medical Inc.
$263.8K 276 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Sterilmed, Inc.
Sterilmed, Inc. reported $263,768.67 across General Payments, Research, and Ownership to 260 physicians and teaching hospitals across 260 transactions.
- $263.8K Above-median payer
- All-tracks total
- 260 Above-median volume
- Transactions
- 260 Above-median reach
- Recipients
- +$147.8K
- General Payments vs PY2023
Sterilmed, Inc. reported $263,768.67 across all CMS Open Payments tracks (General + Research + Ownership) to 260 physicians and teaching hospitals in Program Year 2024 - ranking #916 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $263,768.67, averaging $1.0K per recipient.
Sterilmed, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
12/100
Total payments
F
12/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sterilmed-inc Sterilmed, Inc.
$263.8K · #916/1,925 · 0.0% industry · PY2024
- TOT $263.8K
- RANK #916
- SHARE 0.0%
- TXN 260
- RCP 260
- CAT 1
- GEN $263.8K
- ΔGEN +$147.8K
- TOP1 14.9%
- PY 2024
Volume peers
Nearest volume peer: Creo Medical Inc. ($263.8K)
Sterilmed, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Sterilmed, Inc.'s CMS-reported General Payments increased by $147.8K (+127.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: STERILMED, INC.PY2023: STERILMED, INC.PY2024: Sterilmed, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $115,950.03
- PY2024
- $263,768.67
What the Data Shows for Sterilmed, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Sterilmed, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $263.8K, accounting for 100.0% of this company's General Payments and 260 transactions.
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Sterilmed, Inc.'s 1-category general-payment breakdown at $263.8K, 100.0% of the reported total.
How Sterilmed, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $263.8K | 260 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $102,531.31 (38.9%) of $263,768.67 in this company's General Payments records across 65 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Sterilmed, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
The Christ Hospital
$39,221.89 across 4 reported transactions
- 2
The Methodist Hospital
$20,700.00 across 1 reported transactions
- 3
University Of Kansas Hospital
$18,800.00 across 1 reported transactions
- 4
St. Josephs Of Atlanta
$13,400.00 across 1 reported transactions
- 5
Parkview Hospital
$10,409.42 across 10 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Sterilmed, Inc. ranks #916 of 1,925 by total payments (top 48% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,290 of 1,838 by HHI (bottom 30% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- ITF Therapeutics LLC : $67.9K total payments, HHI 510
- Active Medical, LLC : $34.6K total payments, HHI 509
- Insight Medical Systems, Inc. : $174.6K total payments, HHI 507
- CoapTech, Inc. : $4.0K total payments, HHI 506
- Otter Pharmaceuticals, LLC : $86.2K total payments, HHI 504
- Minerva Surgical, Inc : $53.9K total payments, HHI 503
- Sterilmed, Inc. (this company) : $263.8K total payments, HHI 500
- Merge Healthcare Incorporated : $6.9K total payments, HHI 499
- Alnylam Pharmaceuticals Inc. : $6.5M total payments, HHI 498
- Nxstage Medical, Inc. : $106.2K total payments, HHI 496
- Adaptive Biotechnologies Corporation : $462.3K total payments, HHI 495
- Iovance Biotherapeutics, Inc. : $114.7K total payments, HHI 489
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Sterilmed, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Sterilmed, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Sterilmed, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
IBSA Pharma Inc.
$263.4K 8,301 recipients
Compare payment profiles
Evolution Spine, LLC
$263.2K 96 recipients
Compare payment profiles
THD America, Inc.
$263.2K 501 recipients
Compare payment profiles
J. Morita USA, Inc.
$263.2K 94 recipients
Compare payment profiles
Endomagnetics Ltd
$263.0K 1,023 recipients
Compare payment profiles
Put this to use
Sterilmed, Inc. ranks #916 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Sterilmed, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.